(VIANEWS) – Shares of MEDINCELL (CAC 40: MEDCL.PA) fell by a staggering 27.27% in 21 sessions from €9.35 to €6.80 at 11:05 EST on Monday, following the last session’s upward trend. CAC 40 is falling 0.03% to €7,490.04, after two sequential sessions in a row of gains.
MEDINCELL’s last close was €6.76, 35.62% below its 52-week high of €10.50.
About MEDINCELL
MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
Earnings Per Share
As for profitability, MEDINCELL has a trailing twelve months EPS of €-0.93.
More news about MEDINCELL (MEDCL.PA).
